{
    "clinical_study": {
        "@rank": "97344", 
        "arm_group": [
            {
                "arm_group_label": "Intracoronary abciximab", 
                "arm_group_type": "Experimental", 
                "description": "Intracoronary administration of an abciximab bolus during primary PCI"
            }, 
            {
                "arm_group_label": "Intravenous abciximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous standard administration of an abciximab bolus during primary PCI"
            }
        ], 
        "brief_summary": {
            "textblock": "Intracoronary abciximab administration during primary percutaneous coronary intervention\n      (pPCI) could offer clinical advantages over the intravenous route. The aim of this study was\n      to assess whether abciximab administration route could influence its anti-inflammatory\n      effects. 87 consecutive STEMI patients candidate to pPCI were randomized to receive an\n      intracoronary or intravenous abciximab bolus. The primary endpoint was the extent of\n      inflammation, measured by C-reactive protein (CRP), VCAM-1 and ICAM-1 levels."
        }, 
        "brief_title": "Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention", 
        "completion_date": {
            "#text": "April 2008", 
            "@type": "Actual"
        }, 
        "condition": "Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "BACKGROUND: intracoronary abciximab administration during primary percutaneous coronary\n      intervention (pPCI) could offer clinical advantages over the intravenous route. Besides\n      antiplatelet effects, abciximab can modulate inflammation via cross-reactivity with\n      GPIIb/IIIa, avb3, and aMb2 receptors. The aim of this study was to assess whether abciximab\n      administration route could influence its anti-inflammatory effects.\n\n      METHODS: 87 consecutive STEMI patients candidate to pPCI were randomized to receive\n      intracoronary (Group A, 47 patients) or intravenous (Group B, 42 patients) abciximab bolus.\n      The primary endpoint was the extent of inflammation, measured by C-reactive protein (CRP),\n      VCAM-1 and ICAM-1 levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  presence of STEMI according to the universal definition of myocardial infarction (7);\n\n          -  hospital admission within 12 hours from symptom onset;\n\n          -  successful treatment by primary PCI, defined as a procedure achieving infarct-related\n             artery (IRA) patency with less than 10% residual coronary stenosis based on visual\n             estimation.\n\n        Exclusion Criteria:\n\n          -  age > 90 years;\n\n          -  cardiogenic shock at admission;\n\n          -  left main as IRA;\n\n          -  saphenous vein graft as IRA;\n\n          -  previous PCI in the last 6 months;\n\n          -  severe renal impairment (eGFR<30ml/min) or dialysis treatment;\n\n          -  thrombolytic drug administration in the last 30 days before admission;\n\n          -  known malignancy diagnosed less than 5 years before admission;\n\n          -  known active infectious, coagulative or systemic inflammatory diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "89", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757457", 
            "org_study_id": "0000004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intracoronary abciximab", 
                "description": "Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI", 
                "intervention_name": "Intracoronary administration of an abciximab bolus during primary PCI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Intravenous abciximab", 
                "description": "Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI", 
                "intervention_name": "Intravenous administration of an abciximab bolus during primary PCI", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Inflammatory Agents", 
                "Abciximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "inflammation", 
            "thrombosis", 
            "platelets", 
            "adhesion molecules", 
            "endothelium"
        ], 
        "lastchanged_date": "December 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Novara", 
                    "country": "Italy", 
                    "state": "Piedmont", 
                    "zip": "28100"
                }, 
                "name": "Ospedale Maggiore della Carit\u00e0"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention.(Molecole di Adesione Nella Sindrome Coronarica Acuta", 
        "overall_official": {
            "affiliation": "AO Maggiore della Carita", 
            "last_name": "Alessandro Lupi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: National Institute of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "C-reactive protein will be evaluated at admission and 48 hours after the primary PCI as marker of the inflammatory reaction", 
            "measure": "Change in C-reactive protein levels from baseline after PCI", 
            "safety_issue": "No", 
            "time_frame": "48h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757457"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Ospedaliero Universitaria Maggiore della Carita", 
            "investigator_full_name": "Lupi Alessandro", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Mortality for all causes at 1year after primary PCI", 
                "measure": "Overall Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "1year"
            }, 
            {
                "description": "Target vessel revascularization at 1 year after primary PCI", 
                "measure": "Target vessel revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Recurrent Myocardial infarction 1 year after PCI", 
                "measure": "Myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Azienda Ospedaliero Universitaria Maggiore della Carita", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Azienda Ospedaliero Universitaria Maggiore della Carita", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}